久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

澳大利亞Bionomics  
是一個(gè)生產(chǎn)的藥物發(fā)現(xiàn)和開(kāi)發(fā)新的治療癌癥和嚴(yán)重的疾病，中樞神經(jīng)系統(tǒng)（CNS）通過(guò)應(yīng)用其專(zhuān)有技術(shù)平臺(tái)MultiCore?, Angene? and ionX?, 多個(gè)候選藥物和癌癥，焦慮癥，多發(fā)性硬化癥和癲癇治療領(lǐng)域的目標(biāo)。

Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore?, Angene? and ionX?, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

Background

Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers and initially established technology platforms in the genomics of epilepsy, angiogenesis and breast cancer.

Using its CNS technologies, Bionomics became the first company in the world to develop a genetic test for Severe Myoclonic Epilepsy of Infants, a "catastrophic" form of epilepsy for which standard treatments are inappropriate.

Using its Angene? cancer target discovery platform, Bionomics has identified over 150 human genes implicated in angiogenesis - the growth in blood vessels that feed tumours.

In 2005, the company achieved significant milestones in applying its technology to drug discovery. Through the acquisition of two companies, Neurofit Preclinical Research and Iliad Chemicals, it became the first company in Australia to establish a fully-integrated small molecule drug discovery platform. The company now has proprietary technologies for each step in the drug discovery process: Target Discovery and Validation, Compound Libraries, High Throughput Screening, Medicinal Chemistry and Preclinical Development.

The company has internal small molecule discovery programs operating in the following four areas: Angiogenesis and Vascular Targeting Agents (Cancer); Anxiety/Epilepsy and Multiple Sclerosis (CNS diseases).

Bionomics has commercial partnerships with a number of leading healthcare companies including Merck Serono, GenMab, Athena Diagnostics, LabCorp, Perkin Elmer, and Genetic Technologies Ltd.